The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 20, 2023

Filed:

Jul. 27, 2020
Applicants:

Institut Pasteur, Paris, FR;

Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;

Sorbonne Université, Paris, FR;

Université Clermont Auvergne, Clermont-Ferrand, FR;

Inventors:

Christine Petit, Paris, FR;

Paul Avan, Clermont-Ferrand, FR;

Sedigheh Delmaghani, Paris, FR;

Jean Defourny, Paris, FR;

Asadollah Aghaie, Paris, FR;

Saaid Safieddine, Paris, FR;

Alice Emptoz, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 8/64 (2006.01); A61K 35/761 (2015.01); C12N 15/86 (2006.01); C12N 7/00 (2006.01); A61K 9/00 (2006.01); A61Q 19/02 (2006.01); A61Q 19/08 (2006.01); A61K 48/00 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 38/1709 (2013.01); A61K 8/64 (2013.01); A61K 9/0019 (2013.01); A61K 9/0046 (2013.01); A61K 35/761 (2013.01); A61K 38/17 (2013.01); A61K 48/00 (2013.01); A61K 48/005 (2013.01); A61K 48/0075 (2013.01); A61Q 19/02 (2013.01); A61Q 19/08 (2013.01); C12N 7/00 (2013.01); C12N 15/113 (2013.01); C12N 15/86 (2013.01); A01K 2217/075 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0306 (2013.01); A61K 2800/91 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2710/10021 (2013.01); C12N 2710/10043 (2013.01); C12N 2750/14143 (2013.01);
Abstract

The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS.


Find Patent Forward Citations

Loading…